Access to positron emission tomography combined with computed tomography in the management of lung cancer in Te Manawa Taki Midland Region of New Zealand
background: This study examines access to 18-F fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT; PET-CT) scans among lung cancer patients. data and methods: Patients diagnosed with lung cancer in 2011–2021 were identified from the Midland Lung Cancer Register and the New Zealand Cancer Registry. Patients were linked to the National Non-Admitted Patient Collection to determine if they underwent PET-CT. Logistic regression was used to estimate the odds ratios of having PET-CT, adjusting for age, gender, ethnicity, year of diagnosis, socio-economic status, cancer stage, cell type, Eastern Cooperative Oncology Group (ECOG) status and comorbidities. results: We identified 613 patients with stage I, 300 with stage II and 3,722 with stages III and IV lung cancer, with 75% of stage I and 68.3% of stage II undergoing PET-CT. PET-CT has become more common over time. Patients aged 80 years and over, Māori, those with frailty (ECOG 2+), and those with stages II–IV of disease were less likely to receive PET-CT. Gender, socio-economic status and comorbidities did not influence the use of PET-CT. conclusion: PET-CT is a standard of care for patients with early-stage lung cancer, suitable for curative treatment. The disparity of access to PET-CT for Māori needs to be addressed.
Authors
- Janice Wong (ORCID: https://orcid.org/0009-0006-6603-3034)
- 劳春环
- Denise Aitken
- Vithya Yogarajan (ORCID: https://orcid.org/0000-0002-6054-9543)
- Rāwiri Keenan (ORCID: https://orcid.org/0000-0001-8312-8525)
- Charles de Groot
- Lynne Chepulis
- George Laking
- Ross Lawrenson
- Mark Elwood
- Paul Conaglen
Publication Details
- Journal
- New Zealand Medical Journal
- Published
- 2026-11-20
- DOI
- https://doi.org/10.26635/6965.7523
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00